Coala Life closes SEK 20M in a fresh investment round and adds Ebba Fåhraeus to the board.

Sweden Investments 01 November 2017
Share on FacebookShare on Twitter

Coala Life, a Stockholm, Sweden-based medical technology and life science company focusing on heart diagnostics and digital health, announced closing in a SEK 20M ($2.4M) investment round.

The money comes from existing investors, including 20 North Street, Laurent Leksell and Anders Nyrén. At the same time, the company announced co-opting Ebba Fåhraeus as a new member in the board of directors. Ebba Fåhraeus is a CEO of SmiLe Incubator in Lund as well as a member of the Faculty of Medicine at Lund University, Arc Aroma Pure AB, Skandia's General Assembly and Connect Skåne.

Coala Life, founded in 2004 and led by CEO Philip Siberg, has developed a portfolio of solutions based on the Coala, a patented and commercial service for remote monitoring and self-screening of heart sounds and ECG. The Coala is available direct to consumers and the Coala Pro is offered to healthcare professionals to enable smart, digital cardiac assessments.

Prior to this transaction, Coala brought into the company more than $8M in outside funding, with the last investment round closed in February 2017.